Pricing Log in Create free account

Ascendis Pharma A/S (ASND) vs Summit Therapeutics PLC (SMMT)

Ascendis Pharma A/S and Summit Therapeutics PLC are both Biotechnology companies. Ascendis Pharma A/S is the larger, with a market value of $16.6B against $11.3B — 1.5× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Ascendis Pharma A/S trades at 18.3×. Ascendis Pharma A/S grew revenue faster over the last twelve months: 126.0% against −61.0%. Ascendis Pharma A/S has the higher net margin (71.2% vs 0.00%) and the higher return on invested capital (15.1% vs 0.00%). Across the 18 metrics below, Ascendis Pharma A/S leads on 15 and Summit Therapeutics PLC on 3.

Valuation

Metric ASND SMMT Biotechnology median
P/E 18.30 n/m 10.26
P/S 13.47 15,883.80 9.18
P/B 9.78 17.78 2.05
Price to free cash flow 42.14 n/m 24.81
EV/EBITDA 49.51 n/m 0.65
EV/Sales 13.12 15,045.51 8.98
Earnings yield 5.47% (7.78%) (34.89%)
Free cash flow yield 2.37% (4.11%) (24.52%)

Profitability

Metric ASND SMMT Biotechnology median
Gross margin 91.26% 100.00% 65.16%
Operating margin 24.84% 0.00% 0.00%
Net margin 71.20% 0.00% 0.00%
Free cash flow margin 31.97% 0.00% 0.00%
Return on equity 118.44% (192.50%) (50.12%)
Return on assets 44.34% (159.09%) (45.60%)
Return on invested capital 15.07% 0.00% 0.00%

Growth

Metric ASND SMMT Biotechnology median
Revenue growth (TTM) 125.98% (61.03%) 6.26%
EPS growth (last fiscal year) 39.89% (364.52%) 29.88%
Revenue growth, 5-year CAGR 152.47% (46.49%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ASND SMMT Biotechnology median
Debt to equity 0.31 0.00 0.00
Current ratio 2.99 6.96 4.89
Net debt to EBITDA (2.16) 0.65 1.01

Dividend

Metric ASND SMMT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ASND SMMT Biotechnology median
Market cap 16.64b 11.32b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack